Tumor response to immunochemotherapy may spare some head and neck cancer patients radical surgery

Дата публикации: 10-09-2026 07:10:01

Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors responded to neoadjuvant immunochemotherapy (ICT) and who underwent less extensive surgery had high disease-free survival and organ preservation rates, according to a study published in Clinical Cancer Research, authored by Kunyu Yang, MD, director of Union Hospital Cancer Center at Tongji Medical College and Huazhong University of Science and Technology in China, and others.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Perioperative Toripalimab in Stage III Non–Small Cell Lung Cancer	0	14.35	01-09-2026
2	Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non–Small Cell Lung Cancer	0	6.4	01-09-2026
3	Clinical trial to treat rectal cancer spares major surgery	0	8.49	24-08-2026
4	FLOT vs CROSS in Esophageal Adenocarcinoma	0	6.05	01-09-2026
5	FLOT-Induced vs CROSS-Induced Pathological Complete Response	0	8.96	01-09-2026
6	Study identifies potential RAS inhibitor-immunotherapy strategy for pancreatic cancer	0	7.48	23-09-2026
7	Recalibrating “Unresectable” in Pancreatic Cancer	0	12.62	01-09-2026
8	Immunotherapy increases risk for major cardiovascular events	0	10.61	23-09-2026
9	NHS rolls out pembrolizumab for women with advanced cervical cancer	0	6.27	25-06-2026
10	Почему рак шеи и головы при ВПЧ вероятнее до 22 раз и как влияет курение	0	7.56	16-09-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7.22. Источник: medicalxpress.com.